NTR enters the final week of June with an unusual internal tension: its CFO has been buying the stock on the way down, even as the price has dropped nearly 10% over the past month to CAD 87.32.
The insider angle is the standout this week. Nutrien's CFO Mark Thompson has made five separate open-market purchases since late May, picking up shares at prices ranging from roughly CAD 95 down to CAD 90. On May 8, the buying went wider — the CEO Ken Seitz added 3,900 shares at CAD 94.52, an independent director purchased nearly 14,500 shares for close to USD 1 million, and two other senior executives added to their positions on the same day. Net insider buying across the past 90 days totals just over 26,000 shares, worth approximately USD 1.8 million. These are not large transactions relative to Nutrien's market cap, but the consistency and the cluster from multiple executives on a single date signal that management views the current price as cheap rather than as a falling knife.
The short book does not tell a bearish story that would obviously justify the sell-off. Short interest is low — just 0.63% of the free float — though it did tick up roughly 13% in the past week as shares outstanding in the borrow rose from 2.71 million to 3.06 million. Borrowing costs remain negligible at 0.84%, even after jumping 39% on the week and 57% over the past month. Availability in the lending pool is extremely loose at 3,883% — meaning there are roughly 239 million shares available to borrow against a short position of barely 3 million. None of this reads as a crowded short or a borrow-constrained trade. The rising cost to borrow is worth watching, but at under 1% it remains well within routine territory. The uptick in short interest against a falling stock is a modest caution signal, not a dominant one.
The Street picture is harder to assess with confidence. The analyst consensus data in the snapshot is stale — the most recent rating information is over five years old and should not be treated as current guidance. What the valuation multiples do show is a meaningful re-rating downward: the price-to-book multiple has compressed by about 10% over the past 30 days, and the PE ratio has fallen by nearly 9% across the same window, now sitting at roughly 11x. EV/EBITDA at 6.3x is modestly lower on the month. These are not distressed levels, but the compression is consistent with the stock's underperformance. The ORTEX short score of 27.6 ranks in the 85th percentile for short score — meaning the short-side setup is relatively unattractive compared to most stocks in the universe, which aligns with the thin positioning. The EPS surprise factor score of 23 suggests Nutrien has not been a consistent beat story lately, while the dividend score of 92 flags the yield as a relative strength within its peer group.
Peer context reinforces that this is a sector-wide move rather than an NTR-specific collapse. CF fell 3.2% on the week, MOS dropped 2%, and YAR lost 5.2%. DOW and LYB each fell close to 8%. Nutrien's 4.8% weekly decline sits in the middle of that range — worse than Mosaic, better than the chemicals-heavy names. The fertilizer complex is under broad pressure, and Nutrien is moving with it.
The next earnings event is scheduled for August 5. With the stock having dropped through every price level at which the CFO has been buying over the past six weeks, the question heading into that print is whether the insider conviction carries any read-through to the fundamental outlook — or whether potash and phosphate pricing dynamics tell a different story when management reports.
See the live data behind this article on ORTEX.
Open NTR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
